Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

LENZ Therapeutics, Inc. - Common Stock (NQ:LENZ)

46.58 +1.69 (+3.76%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 867,401
Open 45.74
Bid (Size) 46.58 (10)
Ask (Size) 47.45 (7)
Prev. Close 44.89
Today's Range 44.94 - 47.49
52wk Range 16.54 - 47.49
Shares Outstanding 58,102,949
Dividend Yield 30.96%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
LENZ Therapeutics Announces Commercial Product Availability of VIZZ™ in the United States
From LENZ Therapeutics, Inc.
Via GlobeNewswire
Major Insider Sale Casts Shadow on LENZ Therapeutics' Valuation
San Diego, CA – September 27, 2025 – LENZ Therapeutics (NASDAQ: LENZ) is facing heightened scrutiny this week following a significant insider share sale by a major shareholder, Versant Venture Capital... 
Via MarketMinute
Topics Artificial Intelligence

Performance

YTD
+64.7%
+64.7%
1 Month
+18.7%
+18.7%
3 Month
+55.0%
+55.0%
6 Month
+79.1%
+79.1%
1 Year
+96.2%
+96.2%

More News

Read More
LENZ Therapeutics to Present at Upcoming Investor and Medical Conferences
From LENZ Therapeutics, Inc.
Via GlobeNewswire
Earnings Scheduled For May 7, 2025
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why International Money Express Shares Are Trading Higher By Around 54%; Here Are 20 Stocks Moving Premarket
Via Benzinga
LENZ Therapeutics' Eye Drop Scores First FDA Approval For Age-Related Blurred Vision Condition Impacting 128 Million People
Via Benzinga
LENZ Therapeutics Announces US FDA Approval of VIZZ™ for the Treatment of Presbyopia
From LENZ Therapeutics, Inc.
Via GlobeNewswire
Lenz (LENZ) Q2 Revenue Jumps 604%
Via The Motley Fool
LENZ Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
From LENZ Therapeutics, Inc.
Via GlobeNewswire
LENZ Therapeutics Announces NMPA Submission of New Drug Application for LNZ100 in China for the Treatment of Presbyopia
From LENZ Therapeutics, Inc.
Via GlobeNewswire
LENZ Therapeutics and Laboratoires Théa Announce Exclusive License and Commercialization Agreement for LNZ100 in Canada
From LENZ Therapeutics, Inc.
Via GlobeNewswire
LENZ Therapeutics to Present at Upcoming Investor Conferences
From LENZ Therapeutics, Inc.
Via GlobeNewswire
LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia
From LENZ Therapeutics, Inc.
Via GlobeNewswire
LENZ Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
From LENZ Therapeutics, Inc.
Via GlobeNewswire
LENZ Therapeutics to Participate in Upcoming BofA Securities 2025 Health Care Conference
From LENZ Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
LENZ Therapeutics to Report First Quarter 2025 Financial Results and Recent Corporate Highlights on May 7th, 2025
From LENZ Therapeutics, Inc.
Via GlobeNewswire
Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors
From Climb Bio, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
LENZ Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
From LENZ Therapeutics, Inc.
Via GlobeNewswire
Earnings Scheduled For March 19, 2025
Via Benzinga
LENZ Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights on March 19, 2025
From LENZ Therapeutics, Inc.
Via GlobeNewswire
LENZ Therapeutics to Host Commercial Day on April 15, 2025
From LENZ Therapeutics, Inc.
Via GlobeNewswire
LENZ Therapeutics to Participate in Upcoming Investor Conferences
From LENZ Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is LENZ Therapeutics, Inc. - Common Stock publicly traded?
Yes, LENZ Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does LENZ Therapeutics, Inc. - Common Stock trade on?
LENZ Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for LENZ Therapeutics, Inc. - Common Stock?
The ticker symbol for LENZ Therapeutics, Inc. - Common Stock is LENZ on the Nasdaq Stock Market
What is the current price of LENZ Therapeutics, Inc. - Common Stock?
The current price of LENZ Therapeutics, Inc. - Common Stock is 46.58
When was LENZ Therapeutics, Inc. - Common Stock last traded?
The last trade of LENZ Therapeutics, Inc. - Common Stock was at 09/30/25 04:00 PM ET
What is the market capitalization of LENZ Therapeutics, Inc. - Common Stock?
The market capitalization of LENZ Therapeutics, Inc. - Common Stock is 2.71B
How many shares of LENZ Therapeutics, Inc. - Common Stock are outstanding?
LENZ Therapeutics, Inc. - Common Stock has 3B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.